Latest Content

AbbVie’s short-acting psychedelic bretisilocin shows rapid MADRS drops in phase 2a MDD trials, hinting at scalable, supervised depression care.

Explore the brain’s 5 monoamines—beyond serotonin and dopamine—revealing histamine, melatonin, and trace amines shaping sleep, appetite, and mood.

Explore 2026’s fast-moving psych med pipeline: new Alzheimer agitation option, potential novel ADHD therapy, and promising psilocybin for depression.

Lawsuits, research, and clinicians clash over youth screen addiction—learn more about how problematic social platform use evades diagnosis and how we can curb harm.

Experts urge early bipolar disorder treatment, highlighting lithium’s underuse despite neuroprotective, antisuicidal benefits and evidence that delays worsen outcomes and responsiveness.

Phase 2 trial shows elunetirom rapidly eases bipolar depression symptoms with strong response, good tolerability, and FDA Fast Track momentum.

Discover an objective suicide risk assessment for patients denying ideation, using Suicide Crisis Syndrome and staged warning signs to guide earlier intervention.

Blood exosomal microRNA markers reveal oxidative-stress subtypes, predict psychosis conversion, and guide early, targeted treatments like MitoQ.

New DOE RISE rule cuts federal loan limits for graduate nursing, PAs, and social work—threatening workforce diversity and care access.

Explore Pride Month insights on LGBTQ+ and other minoritized patients—social determinants, research, practice tips, and case studies for clinicians, in our June theme.

Review the highlights from last week's meeting of the American Society for Clinical Psychopharmacology.

Phase 3 at-home data show sublingual dexmedetomidine cuts severe agitation in bipolar disorder and schizophrenia, supporting FDA label expansion.

DSM’s future adds biomarkers and context, yet validity remains unresolved—are diagnoses real? Critics urge an evidence-based overhaul.